Mallinckrodt (MNK) Mentioned Cautiously at Citron Research

November 16, 2016 11:39 AM EST

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

(Updated - November 16, 2016 11:42 AM EST)

Mallinckrodt (NYSE: MNK) was mentioned cautiously at Citron Research. The report said a newly published Medicare dashboard proves that:

  • "1. As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically unproven Acthar
  • 2. The CEO of MNK has committed FRAUD by lying to the investing public about the company‚Äôs dependence on the Medicare system.
  • 3. Acthar is now THE MOST EXPENSIVE drug reimbursed by Medicare.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Short Sales, Trader Talk

Related Entities

Citron Research

Add Your Comment